Jul. 27 at 6:09 PM
MapLight
$MPLT met its primary endpoint and still lost two thirds of its value: ZEPHYR delivered PANSS -4.5 pts vs placebo, p=0.015 on the twice-daily dose, but
$BMY Cobenfy did -9.6 and -8.4 in its pivotals,
$NBIX posted 7.5 pts in Phase 2 and
$RVPH 10.1 pts - and the once-daily arm missed. Full breakdown: https://www.merlintrader.com/maplight-therapeutics-collapsed-after-trial/